Exonics Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $483M
Latest Deal Amount

Exonics Therapeutics General Information

Description

Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time treatment that would make a permanent correction of the mutation that causes Duchenne by identifying and correcting exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers, enabling patients to improve their lives and have a lifelong benefit.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 490 Arsenal Way
  • Suite 110
  • Watertown, MA 02472
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Exonics Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 16-Jul-2019 $483M 0000 00000 Completed Clinical Trials - General
2. Early Stage VC (Series A) 08-Nov-2017 0000 0000 00000 Completed Clinical Trials - General
1. Seed Round 27-Feb-2017 $5M $5M Completed Clinical Trials - General
To view Exonics Therapeutics’s complete valuation and funding history, request access »

Exonics Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 000
To view Exonics Therapeutics’s complete cap table history, request access »

Exonics Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Ca
Biotechnology
Watertown, MA
0000
0000 0000-00-00
000000&0 0000

00000000

t, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
Bannockburn, IL
0000 As of 0000
00000
0.00 0000-00-00
000000&0 00000

00000000

iscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ven
0000000000000
San Francisco, CA
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exonics Therapeutics Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Gene Therapies Formerly VC-backed Bannockburn, IL 0000 00000 000000&0 00000
00000000 000000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
0000 000000000000 Venture Capital-Backed Austin, TX 00 000.00 0000000000 000.00
000000000000000 Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
You’re viewing 5 of 60 competitors. Get the full list »

Exonics Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
The Column Group Venture Capital Minority 000 0000 000000 0
To view Exonics Therapeutics’s complete investors history, request access »